Introduction/Title Collaborating for Successful Implementation of a Cellular Therapy Program: A Multi-Departmental Approach Objectives/Background 2017 was a momentous time for those of us in the hematology/oncology field as we witnessed the FDA approval of not one, but two, chimeric antigen receptor (CAR) T-cell immunotherapy drugs; axicabtagene ciloleucel (Yescarta™) and tisagenlecleucel (Kymriah™). While CAR-T therapy is undoubtedly an innovative, breakthrough treatment, hospitals providing CAR-T therapy are challenged to expand or create a Cellular Therapy Program, manage unique and serious life-threatening complications, and navigate the insurance maze for these new historic drugs with price tags between $373,000 and $475,000, not including the inpatient and outpatient care that accompanies this novel therapy. Methods As the hematology/oncology field anticipated FDA approval of this groundbreaking therapy, our NCI-designated Comprehensive Cancer Center was invited to apply as a Yescarta™-approved hospital. We held early discussions with key leadership in our organization in order to receive the full support to organize and implement a Cellular Therapy Program. After leadership support was established, planning continued with key personnel from essential departments hospital-wide. Implementation was a multidisciplinary, multi-departmental initiative and included Marketing and Public Relations, Pharmacy, Cellular Therapy Laboratory, Apheresis, Medical Intensive Care Unit (ICU), and Hematology and Bone Marrow Transplant (BMT) Inpatient and Outpatient staff. Once formed, the team held weekly meetings with agenda items that included: determining stakeholders, establishing policies and procedures, planning marketing and public relations, developing administrative (i.e. insurance pre-authorization) and clinical patient flow process, and creating patient, family, and staff education. The team elected to expand our existing Stem Cell Transplant Program to include other cellular-based therapies like CAR-T therapy. Results At present, we are one of 61 approved Yescarta™ sites in the US and 17 patients have received CAR-T therapy at our organization. The team understood that it was imperative to include key participants from each area of the hospital that would ultimately be affected. There was consistent attendance at weekly meetings; each discipline and division made an impactful contribution that led to the successful implementation of our cellular therapy program. Conclusions Early and on-going planning has proven key to the success in this multidisciplinary, multi-departmental initiative. Additional commercial cellular therapy based products are becoming increasingly available, and our institution is poised and well prepared to expand and incorporate these products into use modeling our current collaborative initiative.